Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast

Eur J Pharmacol. 1991 Jun 18;199(1):141-2. doi: 10.1016/0014-2999(91)90652-7.

Authors

P J Silver¹, E D Pagani, L de Garavilla, G S Van Aller, M L Volberg, P F Pratt, R A Buchholz

Affiliation

¹ Department of Cardiovascular Pharmacology, Sterling Research Group, Rensselaer, NY 12144.

PMID: 1654265
DOI: 10.1016/0014-2999(91)90652-7

No abstract available

MeSH terms

3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
Animals
Blood Pressure / drug effects
Drug Tolerance
In Vitro Techniques
Male
Muscle Relaxation / drug effects
Muscle, Smooth, Vascular / drug effects*
Nitroglycerin / pharmacology*
Purinones / pharmacology*
Rats
Rats, Inbred Strains

Substances

Purinones
3',5'-Cyclic-GMP Phosphodiesterases
Nitroglycerin
zaprinast